SCHEMBL4921677

SCHEMBL4921677

CCCOC1[C]Oc2ccccc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
KMT2A Q03164 7/20 0.33
MEN1 O00255 5/20 0.33
ALDH1A1 P00352 2/20 0.33
KCNA3 P22001 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPT P10636 2/20 0.32
KDM4E B2RXH2 1/20 0.32
USP2 O75604 1/20 0.32
ADRA2A P08913 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
ADRA1B P35368 1/20 0.32
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
CHRM2 P08172 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4922503 0.90 KCNA3 (0.38) KMT2AMEN1ALDH1A1KCNA3TSHR
SCHEMBL4918721 0.86 KMT2A (0.33) HTR2CHTR2BKMT2AMEN1KCNA3
SCHEMBL4911794 0.76 MAOA (0.34)
SCHEMBL27535325 0.71 ALDH1A1 (0.46) HTR2CHTR2BKMT2AMEN1ALDH1A1
SCHEMBL4722732 0.68 MEN1 (0.42) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4719813 0.68 BCHE (0.37) HTR2BKMT2AMEN1TSHRSMN1; SMN2
SCHEMBL3373132 0.67 MAOA (0.37) KMT2AMEN1USP2
SCHEMBL4723855 0.67 MEN1 (0.41) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4723614 0.67 MEN1 (0.41) KMT2AMEN1TSHRSMN1; SMN2NPSR1
SCHEMBL4720342 0.67 KMT2A (0.33) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PFIZER INC. 2008-08-21 US disclosed
EP-1866317-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2007-12-19 EP disclosed
WO-2006103555-A1 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200475-A1 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors PF4, TBXA2R, P2RY4 HTR2C 375/4885HTR2B 425/4885KMT2A 2100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.